Efficacy of tofacitinib as a «rescue therapy» in patients with severe ulcerative colitis
D. V. Podolskaya,
M. V. Shapina,
T. A. Baranova,
I. A. Tishaeva,
T. L. Alexandrov,
O. V. Knyazev,
B. A. Nanaeva https://doi.org/10.33878/2073-7556-2021-20-3-43-50
Abstract
AIM: to evaluate the effectiveness of tofacitinib as a second line treatment.
PATIENTS AND METHODS: the study included 12 patients, 4 (33.34%) males and 8 (66.66%) females. The median age was 41 ± 5 years. All patients admitted to the hospital with a severe flare-up of ulcerative colitis, which was the inclusion criterion in this study. Clinical manifestations, laboratory parameters, and colonoscopy were done at the time of administration of tofacitinib, on days 3 and 7, and after 12 weeks.
RESULTS: a fast clinical response on 3 day of treatment, reduction in stool frequency, decrease blood in stool was noted in 10 (83.3%) patients. After 7 days from the start of TFCS therapy, all patients showed a decrease from severe activity to mild activity, as well as a decrease in inflammatory blood markers and hemoglobin levels. During the follow-up for 12 weeks, 100% of patients showed positive clinical and laboratory changes. In 10 (83.4%) patients, remission or maintenance of negligible minimal activity was noted.
CONCLUSION: the results obtained show that the use of TFTB in hormone-resistant patients can be effective as a second line of “rescue therapy”.
About the Authors
D. V. Podolskaya
Ryzhikh National Medical Research Center of Coloproctology
Russian Federation
Russian Federation
Darya V. Podolskaya
Salyama Adilya str., 2, Moscow, 123423
M. V. Shapina
Ryzhikh National Medical Research Center of Coloproctology
Russian Federation
Russian Federation
Marina V. Shapina
Salyama Adilya str., 2, Moscow, 123423
T. A. Baranova
Ryzhikh National Medical Research Center of Coloproctology
Russian Federation
Russian Federation
Tatyana A. Baranova
Salyama Adilya str., 2, Moscow, 123423
I. A. Tishaeva
Ryzhikh National Medical Research Center of Coloproctology
Russian Federation
Russian Federation
Irina A. Tishaeva
Salyama Adilya str., 2, Moscow, 123423
T. L. Alexandrov
Ryzhikh National Medical Research Center of Coloproctology
Russian Federation
Russian Federation
Timofey L. Alexandrov
Salyama Adilya str., 2, Moscow, 123423
O. V. Knyazev
Ryzhikh National Medical Research Center of Coloproctology; Moscow Clinical Scientific Center named after A.S. Loginov
Russian Federation
Russian Federation
Oleg V. Knyazev
Salyama Adilya str., 2, Moscow, 123423
shosse Entusiastov, 86, Moscow, 111123
B. A. Nanaeva
Ryzhikh National Medical Research Center of Coloproctology
Russian Federation
Russian Federation
Bella A. Nanaeva
Salyama Adilya str., 2, Moscow, 123423
References
1. Ivashkin V.T., Shelygin Yu.A., Belousova E.A., Abdulganieva D.I., et al. Project: clinical guidelines for the diagnostics and treatment of ulcerative colitis. Koloproktologia. 2019;18(4):7–36. https:// doi.org/10.33878/2073-7556-2019-18-4-7-36 (in Russ.).
2. Knyazev O.V., Shkurko T.V., Fadeyeva N.A., et al. Epidemiology of chronic inflammatory bowel disease. Yesterday, today, tomorrow. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2017;139(3):4–12. (in Russ.).
3. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. Journal of Crohn’s and Colitis. Volume 6, Issue 10, 1 December 2012. DOI http:// dx.doi.org/10.1016/j.crohns.2012.09.002.
4. Vorobev G.I., Khalif I.L. Non-specific inflammatory bowel disease. M.: Miklosh, 2008; 400 p. (in Russ.).
5. Knyazev O.V., Churikova A.A. Anti-cytokine therapy and the quality of life in the patients presenting with inflammatory intestinal disorders. Dokazatel’naya gastroenterologia. 2014;2:17–23. (in Russ.).
6. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685–98.
7. Peyrin-Biroulet L, et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: a real world-based study. Dig Liver Dis. 2016;48(6):601–7.
8. D’Amico F, Parigi TL, Fiorino G, et al. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019;12:1756284819848631.
9. Sandborn WJ, Su C, Sands BE, et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–36.
10. Food and Drug Administration. FDA Approves New Treatment for Moderately to Severely Active Ulcerative Colitis. http://www.fda.gov/newsevents/press-announcements/fda-approves-newtreatment-moderatelyseverely-active-ulcerativecolitis Accessed January 21, 2020. Czarska-thorley D. Xeljanz. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/referrals/xeljanz Accessed January, 21, 2020.
11. Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17:139–47.
12. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–84.
13. Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020, Jan 13. doi: 10.1053/j.gastro.2020.01.007. [Epub ahead of print.]
14. Narula N, Marshall JK, Colombel JF, et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016;111:477–91.
15. Narula N, Fine M, Colombel JF, Marshall JK, Reinisch W. Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks? Inflamm Bowel Dis. 2015;21:1683–94.
16. Berinstein JA, Steiner CA, Regal RE, et al. Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17:988–90.e1.
17. Kotwani P, Terdiman J, Lewin S. Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience. J Crohns Colitis. 2020, Feb 5. DOI: 10.1093/ecco-jcc/jjaa018. [Epub ahead of print.]
18. Paschos P, Katsoula A, Giouleme O, et al. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol. 2018;31:572–82.
19. Lohan C, Diamantopoulos A, LeReun C, el al. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol. 2019;6:e000302.
20. Singh S, Murad MH, Fumery M, et al. First- and second line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020. doi: 10.1016/j.cgh.2020.01.008
21. Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020, Jan 13. DOI: 10.1053/j.gastro.2020.01.007.
22. Food and Drug Administration. Safety Trial Finds Risk of Blood Clots in the Lungs and Death With Higher Dose of Tofacitinib [Xeljanz, Xeljanz XR] in Rheumatoid Arthritis Patients; FDA to Investigate. https://www.fda.gov/drugs/drug-safety-and-availability/safety-trial-finds-risk-blood-clots-lungsanddeath-higher-dose-tofacitinib-xeljanz-xeljanzxr Accessed January 21, 2020.
23. Belousova E.A., Abdulganieva В.I., Alekseeva O.P., et al. Experience of tofacitinib using in therapy of ulcerative colitis in real clinical practice. Koloproktologia. 2019;18(4):86–99. https://doi.org/10.33878/2073-7556-2019-18-4-86-99 (in Russ.).
24. Taxonera С, Olivares D, Alba C. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis. 2021 Feb 15;izab011. DOI: 10.1093/ibd/izab011
25. D’Amico F, Peyrin-Biroulet L, Danese S. Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going. Journal of Crohn’s and Colitis. 2020,1–3. DOI: 10.1093/ecco-jcc/jjaa028
26. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110:1324-1338.
27. Hanauer S, Panaccione R, Danese S et al. Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcer-ative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2. Journal of Crohn’s and Colitis.
Review
For citations:
Podolskaya D.V., Shapina M.V., Baranova T.A., Tishaeva I.A., Alexandrov T.L., Knyazev O.V., Nanaeva B.A. Efficacy of tofacitinib as a «rescue therapy» in patients with severe ulcerative colitis. Koloproktologia. 2021;20(3):43-50. https://doi.org/10.33878/2073-7556-2021-20-3-43-50
Views:
719
Email this article 
